TELO

Telomir Pharmaceuticals, Inc. Common Stock

1.14

USD

TELO Earnings Reports

Positive Surprise Ratio

TELO beat 2 of 4 last estimates.

50%

Next Report

Next Week

Date of Next Report

Feb 02, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.07

Implied change from Q3 25 (Revenue/ EPS)

+133.33%

Implied change from Q4 24 (Revenue/ EPS)

-22.22%

Telomir Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, TELO reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.07 USD, resulting in a 57.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.65% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an increase of 133.33% EPS, and increase of 0.00% in Revenue from the last quarter.

FAQ

What were Telomir Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Telomir Pharmaceuticals, Inc. Common Stock reported EPS of -$0.03, beating estimates by 57.98%, and revenue of $0.00, 0% as expectations.

How did the market react to Telomir Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 3.65%, changed from $1.37 before the earnings release to $1.42 the day after.

When is Telomir Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 02, 2026.

What are the forecasts for Telomir Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 3 analysts, Telomir Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.